À propos des lignes directrices
The Development of the Guidelines, Implementation & Evaluation
The Hypertension Canada Guidelines are developed through a highly structured and systematic process designed to minimize bias. The Guidelines Committee comprises a number of subgroups, each with a librarian who conducts systematic literature searches. The evidence collected is graded using an evidence-based grading scheme and draft guidelines are developed. The draft guidelines are reviewed by the Central Review Committee (CRC), the members of which are unbiased experts in evidence-based medicine and clinical epidemiology, to ensure that the guidelines are developed through a consistent approach. The CRC may suggest revisions to the subgroups.
The draft guidelines and supporting evidence are presented by the CRC to Guidelines Committee members in attendance at a consensus meeting, and there may ile further revisions. The finalized draft guidelines are then put forward for electronic voting by the full Guidelines Committee, and must achieve greater than 70% support to be adopted. The adopted guidelines are then published, and their dissemination is supported by short summaries, handouts, posters, pocket cards, advertisements, educational slide kits, textbooks, and workshops that can be easily understood and used by healthcare professionals.
The Research Evaluation Committee examines outcomes data across Canada related to hospitalization and mortality; awareness and treatment of hypertension; diagnosis of hypertension; national prescriptions of antihypertensive medication; and the economics of hypertension in order to assess the impact of the Hypertension Canada Guidelines.
Why the process is important
Le processus des lignes directrices d’Hypertension Canada met à jour les recommandations de pratique clinique tous les cinq ans pour tenir les mécanismes de gestion et de prévention à jour avec les recherches actuelles. La capacité de réexaminer les questions litigieuses et d’examiner les nouvelles données probantes à cette fréquence donne lieu à des lignes directrices crédibles et actuelles auxquelles font référence les membres d’Hypertension Canada et l’ensemble de la communauté des professionnels de la santé au Canada et dans le monde entier. Le Comité des lignes directrices est multidisciplinaire et comprend des pharmaciens, des médecins de famille, des infirmières et d’autres spécialistes médicaux. L’ensemble de compétences collectives comprend une expertise en hypertension, en santé publique, en formation continue en santé, en traduction des connaissances, en épidémiologie, en recherche sur les résultats et dans des disciplines spécifiques dans le cadre de l’hypertension. La messagerie est adaptée à des disciplines de soins de santé spécifiques.
AGREE II assessment of Hypertension Canada Guidelines process
|AGREE Il item|
|Domain 1. Scope and Purpose|
|The overall objective(s) of the guideline is (are) specifically described||The Hypertension Canada Guidelines process provides updated evidence-based clinical practice guidelines every 5 years for health care professionals, with the ultimate goal of improving hypertension prevention, detection, and management in Canada.|
|The health question(s)
covered by the guideline is (are) specifically described.
|These are described in each guideline section (e.g. diagnosis and treatment recommendations arranged by subsection). Health questions are selected for inclusion based upon their importance to hypertension diagnosis and management and also based upon the availability and quality of the underlying evidence. As such, important health questions for which there are no data to inform a guideline may not be included.|
|The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described.||The guideline is primarily meant to apply to adult Canadians who are at risk for or who have hypertension|
|Domain 2. Stakeholder Involvement|
|The guideline development group includes individuals from all the relevant professional groups.||The Guidelines Committee is a multidisciplinary panel comprised of 2 co-chairs and 16 subgroups (in 2018). Subgroup members, considered content experts in their fields, are responsible for reviewing annual search results and, if indicated, drafting new guidelines or proposing changes to old guidelines. An independent central review committee of methodology experts who have no industry affiliations separately review, grade, and refine proposed guidelines, which are then presented at a 1-day consensus conference. Members of C-CHANGE, the Canadian Task Force on Preventive Health Care, Canadian Diabetes Association Guidelines Committee, Canadian Society of Nephrology, Canadian Stroke Network, and the Canadian Cardiovascular Harmonized National Guideline Endeavour Initiative also collaborate with Hypertension Canada Guidelines subgroup members to ensure harmonization of guidelines between organizations.|
|The patients’ views and preferences have been sought.||Currently, no formal mechanism is in place but ways to incorporate patients’ views and preferences are being considered for future iterations.|
|The target users of the guideline are clearly defined.||These guidelines focus on adult care and are predominantly targeted toward primary care providers. Educational materials based on the hypertension guidelines and designed for patient and public education have been developed to assist health care professionals managing hypertension.|
|Systematic methods were used to search for evidence.||A systematic literature search is performed by a Cochrane Collaboration librarian in MedLine/PubMed using text words and MeSH headings. Search terms include hypertension [MeSH], hypertens*[ti, ab], and blood pressure; these are combined with topic-specific terms to generate search results for each subgroup to review. Bibliographies of identified articles are also manually searched. Randomized controlled trials and systematic reviews of randomized trials are reviewed for treatment recommendations and cross-sectional and cohort studies are reviewed for assessing diagnosis and prognosis. Searches are performed annually.|
|The criteria for selecting the evidence are clearly described.||Cardiovascular morbidity and mortality and total mortality outcomes are prioritized. For health behaviour guidelines, BP is considered an acceptable surrogate and, in patients with CKD, progressive renal impairment is considered to be a clinically important outcome. Study characteristics and study quality are assessed using prespecified, standardized algorithms developed by Hypertension Canada for critical appraisal of randomized controlled trials and cohort studies.|
|The strengths and limitations of the body of evidence are clearly described.||Guidelines are graded according to the strength of their underlying evidence ranging from Grade A (strongest evidence, based on high-quality randomized clinical trials) to Grade D (weakest evidence, based on low power, imprecise studies or expert opinion alone). Details are provided in the Supplementary Appendix of the main manuscript.|
|The methods for formulating the guidelines are clearly described.||After a 1-day consensus meeting, proposed guidelines are finalized and submitted to all voting members (81 in 2018) of the Guidelines Committee for approval. Members with potential conflicts of interest recuse themselves from voting on specific guidelines. Guidelines receiving more than 70% approval are passed.|
|The health benefits, side effects, and risks have been considered in formulating the guidelines.||These are guideline specific. Additional details are provided in the text following each new guideline.|
|There is an explicit link between the guidelines and the supporting evidence.||See Grading system described above.|
|The guideline has been externally reviewed by experts prior to its publication.||Three external primary care experts review the draft guidelines annually.|
|A procedure for updating the guideline is provided.||The guidelines are updated annually.|
|Domain 4. Clarity of Presentation|
|The guidelines are specific and unambiguous.||Judged by end-user.|
|The different options for management of the condition or health issue are clearly presented.||The guidelines cover the spectrum of hypertension diagnosis and management including health behaviour modification, antihypertensive pharmacotherapy and additional non-blood-pressure-related treatments recommended for reducing global vascular risk.|
|Key guidelines are easily identifiable.||Guidelines are stated explicitly and are separated from background text.|
|The guideline describes facilitators and barriers to its application.||The Education and Implementation Committee, a separate branch of Hypertension Canada, conducts an extensive knowledge translation effort to enhance uptake and applicability of these guidelines. These efforts include knowledge exchange forums, targeted educational materials for primary care providers and patients, and available slide kits and summary documents of all guidelines on this website. Documents are available in French and English. Although the number of primary care providers that directly receive Hypertension Canada Guidelines’ materials on a regular basis has dramatically increased, Hypertension Canada is continuing to address the challenge of identifying and reaching all active primary care providers across Canada, through use of our online platforms and professional networks.|
|The guideline provides advice and/or tools on how the recommendations can be put into practice.||Educational materials based on the Hypertension Canada Guidelines have been designed for patients and the public, and to assist health care practitioners managing hypertension.|
|The potential resource implications of applying the guidelines have been considered.||Hypertension Canada currently does not take economic considerations into account when drafting guidelines.|
|The guideline presents monitoring and/ or auditing criteria.||The Research Evaluation Committee conducts hypertension surveillance studies and reviews existing Canadian health surveys to identify gaps between current and best practices. The Education and Implementation Committee also regularly receives feedback from end users to improve guideline processes and content.|
|Domain 6. Editorial Independence|
|The guideline is editorially independent from the funding body.||The members of the Guidelines Committee are unpaid volunteers who contribute their time and expertise to the biennial development and dissemination of the Hypertension Canada Guidelines. To maintain professional credibility of the content, the process for the development of the guidelines is fully independent and free from external influence. External partners assist with the dissemination of the approved guidelines.|
|Conflicts of interest of guideline development members have been recorded.||Members with potential conflicts of interest recuse themselves from voting on specific guidelines (a list of conflicts for each member and each year can be found in the Supplemental Appendix to the main paper).|